Kelyniam Global, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kelyniam Global, Inc. is a U.S.-based medical device manufacturing company specializing in the design, production, and distribution of custom cranial and craniofacial implants. The company utilizes computer-aided design (CAD) and computer-aided manufacturing (CAM) technologies, including advanced 3D printing and CNC machining, to create precision-fitted implants from medical-grade polymers such as PEEK-Optima. Key products include patient-specific cranial and craniofacial implants for reconstructing or replacing damaged bone structures, with patented Integrated Fixation System (IFS) tabs designed to reduce or eliminate the need for cranial plating, potentially decreasing surgical time and overall costs. Kelyniam also distributes regenerative biomaterials such as Osteopore polycaprolactone burr hole covers, Osteostrip and Osteomesh, and Finceramica customized bone hydroxyapatite cranial implants. Founded in 2005 and headquartered in Canton, Connecticut, Kelyniam serves surgeons, health systems, and payors primarily in the United States. The company is recognized for its expedited delivery capability, able to supply custom implants within 24-48 hours for urgent or rush cases, which positions it as a leader in rapid-turnaround cranial implant technology. Recent developments include significant financial growth in 2024 with a 24.6% revenue increase, driven by expanding hospital adoption and operational improvements. Notably, Kelyniam sponsored medical trainings and completed an FDA audit with only minor observations. In 2025, the company secured FDA 510(k) clearance for Vestakeep®, a novel resorbable bi-calcium phosphate implant, broadening its regenerative product portfolio. Kelyniam is actively expanding its distribution network, targeting new hospitals and undergoing value analytics review at major trauma centers. The company also renewed licensing agreements to enhance its advanced cranial implant product offerings and is focused on strategic partnerships, new product development, and increasing shareholder value through targeted sales and business development investments. Kelyniam Global maintains a workforce of approximately 20 employees under CEO Ross Bjella and continues to drive innovation with its patented product features, rapid manufacturing processes, and commitment to research and development in the cranial and craniofacial medical device sector. The company's integrated approach combining software, precision manufacturing, and expedited delivery supports its mission of delivering custom implant solutions that improve patient outcomes while optimizing surgical efficiency and costs. This description reflects Kelyniam's comprehensive product line, geographic focus, founding and operational history, and latest strategic and financial milestones as of 2025.
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
Kelyniam Global Announces Strong Q1 2026 Financial Results
Kelyniam Global Reports 2025 Financial Results
Kelyniam Global Announces Q3 2025 Financial Results
Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products
Kelyniam Global, Inc. Receives FDA Clearance for Innovative Fusion™ BCP-PEEK Implant
Kelyniam Global Inc. to Present at the Life Sciences Virtual Investor Forum September 18th
Commitment to Investor
Kelyniam Global Announces Q2 2025 Financial Results
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
KELYNIAM ACHIEVES RECORD REVENUE & PROFITABILITY FOR 2024
Kelyniam Global, Inc., ("KLYG") Announces Private Investment to Public Entity ("PIPE") Closure of Securities Offering
Kelyniam Global Releases Q3 Financials, Strong Performance Continues
Kelyniam Global Releases Strong Q2 Financials
Kelyniam Global Releases Q1 Financials
NEOS Cranial LOOP™ Receives FDA Clearance for CustomizedBone™ Use
Strong Fourth Quarter Powers 2023 Kelyniam Financials
Kelyniam Global Releases 3rd Quarter 2023 Financials
Kelyniam Global Releases 2nd Quarter 2023 Financials